Dataset Information


Single-shot single-voxel lactate measurements using FOCI-LASER and a multiple-quantum filter.

ABSTRACT: Measurement of tissue lactate using (1) H MRS is often confounded by overlap with intense lipid signals at 1.3 ppm. Single-voxel localization using PRESS is also compromised by the large chemical shift displacement between voxels for the 4.1 ppm (-CH) resonance and the 1.3 ppm -CH3 resonance, leading to subvoxels with signals of opposite phase and hence partial signal cancellation. To reduce the chemical shift displacement to negligible proportions, a modified semi-LASER sequence was written ("FOCI-LASER", abbreviated as fLASER) using FOCI pulses to permit high RF bandwidth even with the limited RF amplitude characteristic of clinical MRI scanners. A further modification, MQF-fLASER, includes a selective multiple-quantum filter to detect lactate and reject lipid signals. The sequences were implemented on a Philips 3 T Achieva TX system. In a solution of brain metabolites fLASER lactate signals were 2.7 times those of PRESS. MQF-fLASER lactate was 47% of fLASER (the theoretical maximum is 50%) but still larger than PRESS lactate. In oil, the main 1.3 ppm lipid peak was suppressed to less than 1%. Enhanced suppression was possible using increased gradient durations. The minimum detectable lactate concentration was approximately 0.5 mM. Coherence selection gradients needed to be at the magic angle to avoid large water signals derived from intermolecular multiple-quantum coherences. In pilot patient measurements, lactate peaks were often observed in brain tumours, but not in cervix tumours; lipids were effectively suppressed. In summary, compared with PRESS, the fLASER sequence yields greatly superior sensitivity for direct detection of lactate (and equivalent sensitivity for other metabolites), while the single-voxel single-shot MQF-fLASER sequence surpasses PRESS for lactate detection while eliminating substantial signals from lipids. This sequence will increase the potential for in vivo lactate measurement as a biomarker in targeted anti-cancer treatments as well as in measurements of tissue hypoxia.


PROVIDER: S-EPMC4737099 | BioStudies | 2015-01-01

REPOSITORIES: biostudies

Similar Datasets

2018-01-01 | S-EPMC5737628 | BioStudies
1000-01-01 | S-EPMC6218146 | BioStudies
2019-01-01 | S-EPMC6732908 | BioStudies
2019-01-01 | S-EPMC6588007 | BioStudies
2014-01-01 | S-EPMC4020995 | BioStudies
2016-01-01 | S-EPMC5059211 | BioStudies
2019-01-01 | S-EPMC7212034 | BioStudies
2019-01-01 | S-EPMC6289748 | BioStudies
2019-01-01 | S-EPMC6401270 | BioStudies
2015-01-01 | S-EPMC4223020 | BioStudies